INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 10.86 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 2.73M shares, a 440.13% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 8.14M shares, a 11.93% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 976.25K shares, a 30.08% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.45M shares, a 131.36% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 12.17M shares, a 83.88% increase from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.62M shares, a 32.90% decline from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 9.86M shares.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 16.25M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 2.73M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 10.86M shares 10-Q · filed 2026-08-13 | 11.84M shares derived: sum of 3 quarters · filed 2026-08-13 | 13.29M shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 8.14M shares 10-Q · filed 2026-05-14 | 9.11M shares derived: sum of 2 quarters · filed 2026-05-14 | 10.56M shares derived: sum of 3 quarters · filed 2026-05-14 | 11.07M shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 976.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 2.42M shares derived: sum of 2 quarters · filed 2026-03-05 | 2.93M shares derived: sum of 3 quarters · filed 2026-03-05 | 12.17M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 1.45M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.95M shares derived: sum of 2 quarters · filed 2025-11-06 | 11.19M shares 10-Q · filed 2025-11-06 | 11.94M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 504.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 9.75M shares 10-Q · filed 2025-08-14 | 10.50M shares derived: sum of 3 quarters · filed 2025-08-14 | 11.12M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 9.24M shares 10-Q · filed 2025-05-15 | 9.99M shares derived: sum of 2 quarters · filed 2025-05-15 | 10.62M shares derived: sum of 3 quarters · filed 2025-05-15 | 12.21M shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 750.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 1.38M shares derived: sum of 2 quarters · filed 2025-03-20 | 2.97M shares derived: sum of 3 quarters · filed 2025-03-20 | 6.62M shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 625.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 2.22M shares derived: sum of 2 quarters · filed 2024-11-14 | 5.87M shares 10-Q · filed 2024-11-14 | 9.76M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 1.59M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 5.24M shares 10-Q · filed 2024-08-14 | 9.13M shares derived: sum of 3 quarters · filed 2024-08-14 | 10.49M shares derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | 3.65M shares 10-Q · filed 2024-05-09 | 7.54M shares derived: sum of 2 quarters · filed 2024-05-09 | 8.89M shares derived: sum of 3 quarters · filed 2024-05-09 | 10.44M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 3.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 5.25M shares derived: sum of 2 quarters · filed 2024-03-28 | 6.80M shares derived: sum of 3 quarters · filed 2024-03-28 | 9.86M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 1.35M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 2.91M shares derived: sum of 2 quarters · filed 2023-11-09 | 5.97M shares 10-Q · filed 2023-11-09 | 9.98M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-06-30 | 1.55M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 4.62M shares 10-Q · filed 2023-08-10 | 8.62M shares derived: sum of 3 quarters · filed 2024-02-09 | 10.67M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-03-31 | 3.06M shares 10-Q · filed 2023-05-11 | 7.07M shares derived: sum of 2 quarters · filed 2024-02-09 | 9.12M shares derived: sum of 3 quarters · filed 2024-02-09 | 10.17M shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-12-31 | 4.01M shares derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | 6.05M shares derived: sum of 2 quarters · filed 2024-02-09 | 7.11M shares derived: sum of 3 quarters · filed 2024-02-09 | 12.63M shares 8-K · filed 2024-02-09 |
| 2022-09-30 | 2.04M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 3.10M shares derived: sum of 2 quarters · filed 2022-11-10 | 8.62M shares 10-Q · filed 2022-11-10 | 10.14M shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 1.05M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 6.57M shares 10-Q · filed 2022-08-15 | 8.10M shares derived: sum of 3 quarters · filed 2022-08-15 | 10.75M shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 5.52M shares 10-Q · filed 2022-05-13 | 7.04M shares derived: sum of 2 quarters · filed 2022-05-13 | 9.69M shares derived: sum of 3 quarters · filed 2022-05-13 | |
| 2021-12-31 | 1.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 4.17M shares derived: sum of 2 quarters · filed 2022-03-31 | 16.25M shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 2.65M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 14.73M shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 12.08M shares 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |